Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Technology Services » Internet Software Or Services
|AFRM||Affirm Holdings, Inc.||-10.79%||114.52||0.0%||$1997.27m|
|UPST||Upstart Holdings, Inc.||-5.60%||313.40||0.0%||$1650.98m|
|SE||Sea Ltd. (Singapore)||-5.81%||316.72||3.1%||$1335.56m|
|MTCH||Match Group, Inc.||-4.95%||156.49||4.4%||$1126.49m|
|FUTU||Futu Holdings Ltd.||-4.67%||88.86||0.0%||$437.23m|
Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.